The introduction of next-generation sequencing technologies is leading to the discovery of many novel mutational targets in haematological malignancies. Morin et al. 1 recently reported somatic heterozygous mutations within the catalytic SET domain of the histone methyltransferase EZH2 in about 7% of follicular lymphoma (FL) cases. The mutations occurred exclusively at codon 641 (Y641), leading to a marked reduction in the enzymatic activity of EZH2 in vitro. 1 The gene encodes the catalytic subunit of the polycomb repressive complex 2 (PRC2) that mediates trimethylation of lysine 27 on histone H3 (H3K27me3), an epigenetic mark associated with transcriptional silencing. The PRC2/EZH2 complex binds to a specific set of target genes in germinal centre (GC) centroblasts, suggesting a GC-specific EZH2 regulatory programme in normal and malignant B cells. 2 Indeed, DNA-methylation profiling studies in FL by our group and others have shown that PRC2 gene targets in stem cells are significantly overrepresented among the hypermethylated genes in these tumours, linking these two epigenetic mechanisms in FL. 3 The spectrum of cancers with EZH2 mutation is also increasing, with mutations in myeloid disorders leading to reduced or complete loss of H3K27me3 expression consistent with a tumour suppressor role for EZH2. [4] [5] [6] Deregulation of the EZH2-H3K27me3 pathway may also occur by other mechanisms, with over-expression of EZH2 associated with poor outcome in a range of solid tumours. [7] [8] [9] In this study, we set out to determine the prevalence and the prognostic value of EZH2 Y641 variants in a large cohort of patients with FL, and the relationship between mutation and EZH2 and H3K27me3 expression. Lymph node samples from 221 patients with FL were available from the tissue archive at St Barts and London Hospital (London Research Ethical Committee (05/Q0605/140)). Of these, 56 samples were obtained at diagnosis, with 165 samples taken at relapse. The major clinical characteristics of these patients are summarized in Table 1 . We also tested 31 paired pre-and post-transformation lymph node biopsy samples in order to trace the patterns of EZH2 mutation over time.
We first sought to assess the frequency and impact of EZH2 mutations on the clinical outcome of FL patients. The EZH2 mutation status was revealed by bidirectional Sanger sequencing, with mutations confirmed from two independent PCR amplicons. The Y641 mutations were detected in 26 of the 221 (12%) samples examined. The mutation frequency was slightly higher than previously reported, 1 with four different types of non-synonymous mutations leading to the replacement of tyrosine at codon 641 ( Figure 1a ). There was no association between EZH2 mutation and overall survival or time to transformation (Figure 1b) . Similar results were obtained when the patient cohort was restricted to the diagnostic samples (Supplementary Figure S1) . Analysis of the series of paired FL and transformed FL (t-FL) cases revealed mutations in 9 of the 31 patients (29%). A mutation was present in both the FL and t-FL samples in six patients, was restricted to the t-FL biopsy samples in two patients and to the FL sample in a single patient. Although there appeared to be an increased frequency of EZH2 mutation in these paired analyses, there was no association between EZH2 mutation and FL transformation in our FL series (13 mutations in 126 non-transformed cases compared with 13 mutations in 69 cases that subsequently underwent transformation; P ¼ 0.19, Fisher's exact test). As EZH2 has been implicated in direct control of DNA methylation, 10 we went on to test whether mutation had an effect on DNA methylation, using our previously generated FL methylation profiles of paired FL and t-FL samples. 3 Average methylation values across 1264 CpG loci differed by no more than 2% between EZH2 wild-type and EZH2 mutated samples. Although we cannot rule out the possibility of minor effects on methylation, the absence of any major differences suggests that EZH2 mutations have no effect on DNA-methyltransferase recruitment.
In order to assess the effect of EZH2 Y641 codon mutations on EZH2 and H3K27me3 expression, quantitative real-time PCR and western blot analyses were performed on germinal centre B-cell lymphoma cell lines SU-DHL-4 (Y641S), SU-DHL-6 (Y641N), Karpas-422 (Y641N), DOHH-2 (wild-type), SC-1 (wild-type), and on six diagnostic FL lymph node samples, two benign B-lymphoblastoid cell lines (Nc-Nc, HRC57) and four reactive tonsils. No differences were seen in the EZH2 mRNA expression levels between the mutated, wild-type and control samples (Figure 2a (Figure 2c ), supporting the notion that mechanisms other than gene mutation are affecting EZH2-H3K27me3 levels. 11, 12 As several studies have reported the regulation of EZH2 by miR-101 13 and miR-26a, 14 we tested whether the expression of these microRNAs could account for the variable Meier plots for overall survival and time to transformation by EZH2 mutation status. There were no significant associations observed between these clinical parameters and the EZH2 mutation status. The survival estimates were obtained using the GraphPad Prism Version 5.0 software (La Jolla, CA, USA), and the log-rank (Mantel-Cox) test was used to evaluate differences between EZH2 mutated and wild-type subgroups. P-values o0.05 were considered significant. Overall survival was defined as the time from diagnosis to death, censored at last follow-up. Transformation to aggressive lymphoma was defined histologically or by clinical criteria. Letters to the Editor EZH2-H3K27me3 expression. Although we observed a 100-fold difference in both miR-101 and miR-26a expression levels across samples, these did not correlate with EZH2 levels in either t(14;18)-positive cell lines or FL primary material (data not shown). Whereas in myeloid malignancies EZH2 mutation leads to a clear loss of function, [4] [5] [6] Morin et al. previously showed that Y641 mutations result in a reduction of the H3K27 trimethylation capacity in vitro. 1 In contrast, our results showed H3K27me3 expression in all FL samples irrespective of their mutation status (Figure 2b ), suggesting that these Y641 mutations are unlikely to behave in a dominant-negative fashion in FL. The exact mechanism by which the EZH2 Y641 mutations contribute to GC lymphomagenesis is still therefore open to question.
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